Title: The clinical value of serum sirtuin-1 concentration in the diagnosis of metabolic
dysfunction-associated steatotic liver disease
Version: 0 Date: 15 Nov 2024
Reviewer's report:
The study showed that serum Sirt-1 levels were lower in patients with MASLD which could
assist in detecting patients with MASLD.
In the abstract section, please add the missing abbreviation (ROC). Additionally, add the missing
abbreviations in whole manuscript such as SREBP-1c, ACC, FAS, HCC, and ER.
In the background section, correct the abbreviation metabolic-dysfunction associated
steatohepatitis (MSH) to be (MASH).
In the background section, you stated that "on the other hand, the decreased expression of
the Cyrtuin1 gene and its serum levels were associated with an increase in the expression of
lipogenic genes, obesity, insulin resistance, lipid and cholesterol levels, as well as inflammation
and oxidative stress [15]". Correct Cyrtuin1 gene to be Sirtuin1 gene.
In the background section, you mentioned previous study that had been reported a decrease in
the expression of Sirt-1 and reduced plasma levels in people with MASLD, and its association
with an increased degree of hepatic steatosis. Please explain the novelty of this study in the aim
of your study.
In the results section, Table 2: Correlations between serum Sirtuin-1 levels and biochemical
parameters in the whole study samples (n=90). Correct the study samples number (n=90) into
(n=190).
In the results section (Tables), correct the unit (mg/dl) to be (mg/dL).
In the results section, Table 3 was showed the sensitivity and specificity for the diagnostic values
of serum sirtuin-1 levels in prediction of MASLD. Please add the accuracy for the diagnostic
values of serum sirtuin-1 levels in prediction of MASLD in table 3.
In the results section, Table 4: Association and agreement between serum Sirtuin-1 cutoff levels
and the presence of MASLD. Please explain what the p-value (p=< 0.001*) represent and also
Kappa agreement.
Title: The clinical value of serum sirtuin-1 concentration in the diagnosis of metabolic
dysfunction-associated steatotic liver disease
Version: 0 Date: 15 Nov 2024
Reviewer's report:
The study showed that serum Sirt-1 levels were lower in patients with MASLD which could
assist in detecting patients with MASLD.
In the abstract section, please add the missing abbreviation (ROC). Additionally, add the missing
abbreviations in whole manuscript such as SREBP-1c, ACC, FAS, HCC, and ER.
In the background section, correct the abbreviation metabolic-dysfunction associated
steatohepatitis (MSH) to be (MASH).
In the background section, you stated that "on the other hand, the decreased expression of
the Cyrtuin1 gene and its serum levels were associated with an increase in the expression of
lipogenic genes, obesity, insulin resistance, lipid and cholesterol levels, as well as inflammation
and oxidative stress [15]". Correct Cyrtuin1 gene to be Sirtuin1 gene.
In the background section, you mentioned previous study that had been reported a decrease in
the expression of Sirt-1 and reduced plasma levels in people with MASLD, and its association
with an increased degree of hepatic steatosis. Please explain the novelty of this study in the aim
of your study.
In the results section, Table 2: Correlations between serum Sirtuin-1 levels and biochemical
parameters in the whole study samples (n=90). Correct the study samples number (n=90) into
(n=190).
In the results section (Tables), correct the unit (mg/dl) to be (mg/dL).
In the results section, Table 3 was showed the sensitivity and specificity for the diagnostic values
of serum sirtuin-1 levels in prediction of MASLD. Please add the accuracy for the diagnostic
values of serum sirtuin-1 levels in prediction of MASLD in table 3.
In the results section, Table 4: Association and agreement between serum Sirtuin-1 cutoff levels
and the presence of MASLD. Please explain what the p-value (p=< 0.001*) represent and also
Kappa agreement.
Please review this paper.
user
Title: The clinical value of serum sirtuin-1 concentration in the diagnosis of metabolic
dysfunction-associated steatotic liver disease
Version: 0 Date: 15 Nov 2024
Reviewer's report:
The study showed that serum Sirt-1 levels were lower in patients with MASLD which could
assist in detecting patients with MASLD.
In the abstract section, please add the missing abbreviation (ROC). Additionally, add the missing
abbreviations in whole manuscript such as SREBP-1c, ACC, FAS, HCC, and ER.
In the background section, correct the abbreviation metabolic-dysfunction associated
steatohepatitis (MSH) to be (MASH).
In the background section, you stated that "on the other hand, the decreased expression of
the Cyrtuin1 gene and its serum levels were associated with an increase in the expression of
lipogenic genes, obesity, insulin resistance, lipid and cholesterol levels, as well as inflammation
and oxidative stress [15]". Correct Cyrtuin1 gene to be Sirtuin1 gene.
In the background section, you mentioned previous study that had been reported a decrease in
the expression of Sirt-1 and reduced plasma levels in people with MASLD, and its association
with an increased degree of hepatic steatosis. Please explain the novelty of this study in the aim
of your study.
In the results section, Table 2: Correlations between serum Sirtuin-1 levels and biochemical
parameters in the whole study samples (n=90). Correct the study samples number (n=90) into
(n=190).
In the results section (Tables), correct the unit (mg/dl) to be (mg/dL).
In the results section, Table 3 was showed the sensitivity and specificity for the diagnostic values
of serum sirtuin-1 levels in prediction of MASLD. Please add the accuracy for the diagnostic
values of serum sirtuin-1 levels in prediction of MASLD in table 3.
In the results section, Table 4: Association and agreement between serum Sirtuin-1 cutoff levels
and the presence of MASLD. Please explain what the p-value (p=< 0.001*) represent and also
Kappa agreement.
assistant